Groupama Asset Managment Cytokinetics Inc Transaction History
Groupama Asset Managment
- $6.04 Trillion
- Q2 2025
A detailed history of Groupama Asset Managment transactions in Cytokinetics Inc stock. As of the latest transaction made, Groupama Asset Managment holds 350,000 shares of CYTK stock, worth $22.3 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
350,000
Previous 350,000
-0.0%
Holding current value
$22.3 Million
Previous $416 Million
8.8%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
385Shares Held
129MCall Options Held
3.62MPut Options Held
1.14M-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.6MShares$1.12 Billion0.37% of portfolio
-
Black Rock Inc. New York, NY14.7MShares$933 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12MShares$762 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA7.83MShares$498 Million0.05% of portfolio
-
State Street Corp Boston, MA6.37MShares$405 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $5.99B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...